58
Participants
Start Date
May 31, 2006
Primary Completion Date
February 28, 2010
Study Completion Date
June 30, 2010
Farletuzumab
Weekly Farletuzumab infusions Dose dependent on dosing group
Chemo Plus Far
Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
New York Oncology Hematology, Albany
Lehigh Valley Women's Cancer Center, Allentown
Johns Hopkins University, Baltimore
Northern Virginia Pelvic Surgery Associates, Annandale
Peninsula Cancer Center, Newport News
Gynecology Oncology Research & Development, Greenville
Gabrail Cancer Center, Canton
St. Vincent Gynecologic Oncology, Indianapolis
Jayne Gurtler, M.D., Metairie
Hematology and Oncology Specialists, LLC, Metarie
Hematology and Oncology Specialists, LLC, Covington
Mary Crowley Medical Research Center, Dallas
Tyler Cancer Center, Tyler
South Texas Oncology & Hematology, San Antonio
Sharp HealthCare, San Diego
The Center for Cancer and Hematologic Disease, Cherry Hill
The Cancer Institute of New Jersey, New Brunswick
Cooper University Hospital, Voorhees Township
Krankenhaus Nordwest, Frankfurt
Nationales Centrum fur Tumorerkrankungen, Heidelberg
Lead Sponsor
Morphotek
INDUSTRY